Worldwide: IGPA 2015 Focuses On Biosimilars, Quality, And Harmonization In Toronto-Part Two Of Two

Last Updated: October 1 2015
Article by Brian J. Malkin

This is the second part of coverage of the 18th Annual International Generic Pharmaceutical Alliance (IGPA) Meeting held in Toronto, Canada on September 16-18, 2015. For additional coverage, see Part One here.

The following day features a panel of chief executive officers from a variety of pharmaceutical companies of different sizes and focus areas. Common themes included ongoing industry consolidation and increasing concern about the supply chain and its impact on product quality. In the U.S., CEOs expressed disappointment with initial returns from GDUFA, which in part occurred because of an underestimation of how large an overhaul FDA's operational systems required. While ICH and other internationally-oriented bodies have made progress with innovator products, the CEOs observed that there has been little harmonization around bioequivalence standards. As a result, generic companies are forced to develop multiple bioequivalence approaches for products, requiring duplicative but somewhat different biostudies, at a cost to development and largely unnecessary biostudies. Regarding biosimilars, there appeared to be consensus that FDA's proposed non-proprietary naming model to include the same core name with a four-letter nonsense code to differentiate reference and biosimilar products would create more barriers for acceptance of biosimilars. For the biosimilars industry to succeed, there needs to be more market uptake, e.g., infliximab in Canada only has sales around $7,000 – clearly not a workable model.

Next, an IGPA panelprovided an overview how IGPA has been working to address trade barriers and promote foreign market access for generic and biosimilar medicines. Keon explained that until recently, the generic industry has gotten to the trade negotiations table late, resulting in imbalances in patent linkage systems and intellectual property rights that favored innovator products. IGPA has assembled a team dedicated to addressing trade relations in a more coordinated manner, Keon said, which it hopes can not only benefit small molecule generics but a developing biosimilar industry make inroads for increased market acceptance and product development. IGPA is also involved in the Trans Pacific Partnership (TPP), which represents 40% worldwide trade, and is a living agreement where more countries can join in such discussions as patent linkage and market protection, e.g., exclusivities. Adrian van den Hoven, Director General, EGA, then described how IGPA and its members have been getting involved in the Transatlantic Trade and Investment Partnership (TTIP) and how it may translate into better access to generic, value-added, and biosimilar products, which are EGA's focus areas.

The final main panel included a regulatory discussion of biosimilars from Dr. Sue Lim, Senior Staff Fellow, Therapeutic Biologics and Biosimilars Team, FDA, Dr. Elena Wolff-Holz, Paul Ehrlich Institute, Member of the EMA Biosimilar Medicinal Products Working Group, and Dr. Ivana Knezevic, Scientist, Group Leader, Norms and Standards for Biologicals, Department of Essential Medicines and Health Products, WHO. Lim explained FDA's general plan for reviewing biosimilars. Interestingly, Lim noted that the only approved biosimilar, Zarxio® no longer had identical indications to its reference product, because a new indication had been added to the referenced product since approval, which would require a supplement to add the new indication. Lim said that FDA plans to issue guidance for interchangeability, labeling, and statistical approaches. Lim also described the goal behind the recent nonproprietary naming proposal, which FDA believed would prevent inadvertent substitution and facilitate pharmacovigilance by encouraging routine use of designated suffixes while avoid potential inaccurate perceptions of safety and effectiveness differences of biological products based on the licensure pathway. When asked about FDA's proposed naming policy and whether NDC codes were suggested as a possible suffix, Lim said that it was considered, but FDA did not think it was adequate and could not comment further on it. Lim said that in the U.S., FDA heard that non–proprietary naming was used more than brand names, which is why FDA believes it is more critical for pharmacovigilance.

Lim suggested that biosimilar sponsors come to FDA with a plan to address product differences in advance–"don't just hope for the best." Lim also suggested that sponsor be transparent and share feedback from each regulatory authority, as questions to seek clarity and note program differences. Lim said that while sponsors may request parallel scientific advice for biosimilar development, while regulators from different countries may strive for alignment on scientific concepts, she cautioned that they may not be able to harmonize advice and will note similarities and differences.

Wolff-Holz picked up on Lim's comment that while there has been U.S. and EU convergence on the step-wise process and totality of circumstances, there are still regulatory differences. In the EMA, for example, there is alignment with FDA that there is no regulatory requirement for biosimilarity after granting authorization, e.g., like with Zarxio®, indications added to the reference product after approval of the biosimilar are not automatically added to the biosimilar product, even though there may be that option with extrapolation in a supplemental application. The EMA appears to have a different plan for pharmacovigilance tied to the brand name and batch number, whereas FDA appears to be looking to nonproprietary naming, which goes against EMA policy to avoid proliferation of local drug substance nomenclature. And the various regions also differ on what is considered a biosimilar product, e.g., enoxaparin is regulated as a drug by FDA but as a biologic in the EMA and by Health Canada.

When asked about the difference in extrapolating indications for infliximab in the EMA and Health Canada, Wolff-Holz noted that while both agencies agree in the concept of extrapolation, there were different scientific viewpoints on a single test for a possible mechanism of action for irritable bowel disease result that showed perhaps a 20% difference. The EMA and other countries where this product is approved thought that in the totality of the data, this difference was not clinically meaningful, but Health Canada differed. Wolff-Holz added that Health Canada may ultimately reach the same conclusion once Celltrion provides additional data, which has been requested.

Knezevic explained how the WHO gets involved in biosimilars and biological reference materials and standardization of assays and quality control tests to help standardize biological products worldwide. From her viewpoint, one of the dangers has been that in some countries, biological products are called "biosimilar" when there is no reference biological product in that country, calling this a "fake biosimilar," where the term "biosimilar" should not be used. Regarding the extrapolation issue for infliximab, Knezevic agreed that each regulatory authority has right to make its own determinations but thought it is still useful to share information.

In the concluding remarks, IGPA appointed its new Chair and President, Vivian Frittelli, CEO, National Association of Pharmaceutical Manufacturers (South Africa) and venue for next year, Orasac-Dubrovnik, Croatia, held jointly with the EGA's Annual Meeting, from June 8-10, 2016. See you there!

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions